Hologic's FDA-cleared Genius Digital Dx Systems leads AI innovation in cervical cancer prevention

In this episode of DeviceTalks AI, we explore the advancements in AI-driven technologies in women's health and cancer diagnostics. In our keynote interview, we speak with Michael Quick, Vice President of R&D and Innovation in Cytology & Oncology at Hologic. Quick shares his journey from a pre-med student to a leader in cytology innovation. He discusses the development and impact of Hologic’s Genius Digital Diagnostic Systems, the first FDA-approved digital cytology system, which leverages AI to enhance cervical cancer screening accuracy and efficiency. Michael emphasizes Hologic’s dedication to women's health and the critical role of AI in addressing the shortage of skilled cytologists, ensuring faster and more accurate diagnostics for patients worldwide. He also touches on the challenges and opportunities faced during the FDA approval process and the importance of early and collaborative engagement with regulatory bodies. We also hear from Dr. Wael Yared, Chief Technology Officer at Tecan, who highlights Tecan's contributions to cancer research and diagnostics. Dr. Yared elaborates on the company's innovations in liquid biopsy and solid tissue biopsy workflows, which leverage AI to streamline processes and reduce errors. He emphasizes the significance of partnerships in driving medical advancements and the role of AI in personalized medicine and multiomic capabilities. This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about Tecan visit, https://partnering.tecan.com Please subscribe to DeviceTalks AI on all major podcast channels and subscribe to DeviceTalks on YouTube to ensure you never miss an episode. Thank you for listening to DeviceTalks AI!